top of page

News

VascVersa Advances AngiGenix™ Platform Through Successful Gene Editing Proof-of-Concept Study

Nov 13
1 min read

VascVersa is excited to announce the successful completion of a proof-of-concept study supported by the Scottish National Blood Transfusion Service (SNBTS), advancing its proprietary AngiGenix™ platform and demonstrating its design potential for in situ and ex vivo cell therapies. VascVersa has generated a unique and proprietary dataset that maps the genes and molecular pathways involved in blood vessel regeneration, providing the basis for the design of RNA/genetic therapies preventing vision loss by reversing blood vessel dystrophy.


The approach validated the use of the dataset to identify future molecular targets for genetic modulation to facilitate vessel formation. The company will now use the approach as a blueprint for the identification of high-priority targets, conventionally undruggable by other modalities, for taking forward into preclinical development.

VascVersa’s shareholders include QUBIS, the commercialisation arm of Queen’s University Belfast, and Co-Fund NI, managed by Clarendon Fund Managers. Their continued participation reflects strong conviction in the company’s scientific platform and clinical potential. 

The study achieved high precision gene-editing efficiencies with low off-target effects, corroborating how the AngiGenix platform can be used to identify and modulate novel disease pathway targets in a safe manner and confirming the new platform    as a powerful one for the creation of in situ therapies.


To capitalise on the successful proof-of-concept study, VascVersa has strengthened its in-house capabilities through the recruitment of a dedicated molecular scientist who will lead technology transfer from the SNBTS programme, advance the AngiGenix™ platform, and drive the discovery of new gene targets for future development. This milestone strengthens VascVersa's position at the forefront of regenerative medicine, combining proprietary platforms to develop transformative vascular regenerative therapies for vision loss.



 
 
bottom of page